Overall survival for early and locally advanced non-small-cell lung cancer from one institution: 2000–2017

Abstract

Purpose

Lung cancer is the leading cause of cancer death in Spain. The objective of our study was to evaluate the characteristics of patients diagnosed with stages I–III non-small-cell lung cancer, as well as the impact that epidemiological changes, diagnostic improvements and surgical therapeutic innovations have had on survival in the past 20 years.

Methods

Retrospective analysis of patients diagnosed with early and locally advanced non-small-cell lung cancer between years 2000 and 2017 in our institution.

Results

A total of 859 patients were included. An increase in the percentage of women diagnosed over time was observed. Statistically significant differences were observed in the mean age at diagnosis, with a progressive increase in the different periods. The percentage of current or former smokers was similar in all periods. Adenocarcinoma was the most frequent histologic type with a progressive increase in its frequency. The percentage of patients diagnosed in early stages has been increasing over the years. In stages I–II, there was a significant increase in the median survival (29.7 months: 2000–2004, 68.73 months: 2010–2014) that could be seen in stage III as well (14.7 months: 2000–2004, 30.63 months: 2015–2017).

Conclusions

A variation of clinical characteristics of lung cancer in Spain has been observed in recent years, as well as an improvement in survival in early and locally advanced stages, due not only to the treatments, but also to a more accurate detection of these tumors. Little progress has been made in tobacco habit with high stable percentages over the years.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2
Fig. 3
Fig. 4

References

  1. 1.

    Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.

    Article  Google Scholar 

  2. 2.

    Sociedad española de oncología médica (SEOM)—Cifras del cáncer en España 2020 [Internet]. Cited 18 Apr 2020. https://seom.org/dmcancer/cifras-del-cancer/

  3. 3.

    Burns D, Anderson C. Do changes in cigarette design influence the rise in adenocarcinoma of the lung? Cancer Causes Control. 2011;22:13–22.

    Article  Google Scholar 

  4. 4.

    Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, et al. National lung screening trial research team. Reduced lung cancer mortality with low dose computed tomographic screening. N Engl J Med. 2011;365:395–409.

    Article  Google Scholar 

  5. 5.

    West H, Vallières E, Schild S (2020) Management of stage I and stage II non-small cell lung cancer [Internet]. Cited 18 Apr 2020

  6. 6.

    Auperin A, Le Pechoux C, Rolland E, Curran WJ, Furuse K, Fournel P, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J ClinOncol. 2010;28(13):2181–90.

    CAS  Article  Google Scholar 

  7. 7.

    Salmerón D, Chirlaque M, Isabel Izarzugaza M, Sánchez M, Marcos-Gragera R, Ardanaz E, et al. Lung cancer prognosis in Spain: the role of histology, age and sex. Respir Med. 2012;106(9):1301–8.

    Article  Google Scholar 

  8. 8.

    de Cos S, Escuín J. El cáncer de pulmón en España. Epidemiología, supervivencia y tratamiento actuales. ArchBronconeumol. 2009;45:341–8.

    Google Scholar 

  9. 9.

    International Early Lung Cancer Action Program Investigators, Henschke CI, Yip R, Miettinen OS, et al (2006) Women's susceptibility to tobacco carcinogens and survival after diagnosis of lung cancer. JAMA 296(2):180–4

  10. 10.

    Kure EH, Ryberg D, Hewer A, et al. p53 mutations in lung tumours: relationship to gender and lung DNA adduct levels. Carcinogenesis. 1996;17:2201–5.

    CAS  Article  Google Scholar 

  11. 11.

    Fu J, Kau T, Severson R, Kalemkerian G. Lung cancer in women. Chest. 2005;127(3):768–77.

    Article  Google Scholar 

  12. 12.

    Cerfolio R, Bryant A, Scott E, Sharma M, Robert F, Spencer S, et al. Women with pathologic stage I, II, and III non-small cell lung cancer have better survival than men. Chest. 2006;130(6):1796–802.

    Article  Google Scholar 

  13. 13.

    Hecht SS, Szabo E. Fifty years of tobacco carcinogenesis research: from mechanisms to early detection and prevention of lung cancer. CancerPrev Res. 2014;7(1):1–8.

    CAS  Google Scholar 

  14. 14.

    Tammemagi CM, Neslund-Dudas C, Simoff M, Kvale P. Smoking and lung cancer survival: the role of comorbidity and treatment. Chest. 2004;125(1):27–37.

    Article  Google Scholar 

  15. 15.

    Cancer stat facts: Female breast cancer [Internet]. National Cancer Institute: surveillance, epidemiology, and end results program web site (consulted 18 Apr 2020). https://seer.cancer.gov/statfacts/html/breast.html

  16. 16.

    Devesa SS, Shaw GL, Blot WJ. Changing patterns of lung cancer incidence by histological type. Cancer EpidemiolBiomarkPrev. 1991;1(1):29–34.

    CAS  Google Scholar 

  17. 17.

    Stepanov I, Knezevich A, Zhang L, Watson CH, Hatsukami DK, Hecht SS. Carcinogenic tobacco-specific N-nitrosamines in US cigarettes: three decades of remarkable neglect by the tobacco industry. Tob Control. 2012;21(1):44–8.

    Article  Google Scholar 

  18. 18.

    Ries LA. Influence of extent of disease, histology, and demographic factors on lung cancer survival in the SEER population-based data. SeminSurgOncol. 1994;10(1):21–30.

    CAS  Google Scholar 

  19. 19.

    Pignon JP, Tribodet H, Scagliotti GV, Douillard JY, Shepherd FA, Stephens RJ, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE collaborative group. J ClinOncol. 2008;26(21):3552–9.

    Article  Google Scholar 

  20. 20.

    Burdett S, Pignon JP, Tierney J, Tribodet H, Stewart L, Le Pechoux C, et al. Adjuvant chemotherapy for resected early-stage non-small cell lung cancer. Cochrane Database Syst Rev. 2015;3:CD011430.

    Google Scholar 

  21. 21.

    Burdett SS, Stewart LA, Rydzewska L. Chemotherapy and surgery versus surgery alone in non-small cell lung cancer. Cochrane Database Syst Rev. 2007;3:CD006157.

    Google Scholar 

  22. 22.

    Albain KS, Swann RS, Rusch VW, Turrisi AT 3rd, Shepherd FA, Smith C, et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet. 2009;374(9687):379–86.

    CAS  Article  Google Scholar 

  23. 23.

    Van Meerbeeck JP, Kramer GWPM, Van Schil PEY, Legrand C, Smit EF, Schramel F, et al. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. J Natl Cancer Inst. 2007;99(6):442–50.

    Article  Google Scholar 

  24. 24.

    Majem M, Juan O, Insa A, Reguart N, Trigo JM, Carcereny E, et al. SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018). ClinTranslOncol. 2019;21(1):3–17.

    CAS  Google Scholar 

Download references

Funding

This paper is part of a project that has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No. 875160.

Author information

Affiliations

Authors

Contributions

All authors made substantial contributions to the conception or design of the work and the acquisition, analysis and interpretation of data; drafted the work and revised it critically for important intellectual content; approved the version to be published; and agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Corresponding authors

Correspondence to V. Calvo or M. Provencio.

Ethics declarations

Conflict of interest

Dr. M. Provencio has received personal fees from Bristol-Myers Squibb, Merck Sharp & Dohme (MSD), Roche, AstraZeneca and Takeda. Dr. V. Calvo has received personal fees from Bristol-Myers Squibb (BMS), Merck Sharp & Dohme (MSD), Roche, AstraZeneca and Takeda. The other authors do not have conflicts of interest to declare.

Ethical approval

Ethical approval was waived by the local Ethics Committee of Hospital Universitario Puerta de Hierro in view of the retrospective nature of the study.

Informend Consent

Not applicable.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

González, M., Calvo, V., Redondo, I. et al. Overall survival for early and locally advanced non-small-cell lung cancer from one institution: 2000–2017. Clin Transl Oncol (2021). https://doi.org/10.1007/s12094-020-02521-5

Download citation

Keywords

  • Early-stage
  • Locally advanced stage
  • Non-small-cell lung cancer
  • Survival